| RS2124851950 |
GLS
|
Health Risk |
Likely pathogenic |
Infantile cataract, skin abnormalities |
| RS2124857065 |
ARF1
|
Health Risk |
Likely pathogenic |
Periventricular nodular heterotopia 8, Periventricular nodular heterotopia 8 |
| RS2124857424 |
ARF1
|
Health Risk |
Pathogenic |
Periventricular nodular heterotopia 8, Periventricular nodular heterotopia 8 |
| RS2124857427 |
ARF1
|
Health Risk |
Pathogenic |
Periventricular nodular heterotopia 8, Periventricular nodular heterotopia 8 |
| RS2124857932 |
ARF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Periventricular nodular heterotopia 8, Periventricular nodular heterotopia 8 |
| RS2124857939 |
ARF1
|
Health Risk |
Likely pathogenic |
Periventricular nodular heterotopia 8, Periventricular nodular heterotopia 8 |
| RS2124858360 |
ARF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Periventricular nodular heterotopia 8, Periventricular nodular heterotopia 8 |
| RS2124858642 |
CRELD1
|
Health Risk |
Conflicting classifications of pathogenicity |
Inborn genetic diseases, Jeffries-Lakhani neurodevelopmental syndrome |
| RS2124882927 |
UNC80
|
Health Risk |
Pathogenic |
— |
| RS2124894940 |
GLS
|
Health Risk |
Likely pathogenic |
— |
| RS2124895900 |
UNC80
|
Health Risk |
Likely pathogenic |
— |
| RS2124905063 |
SLC6A1
|
Health Risk |
Pathogenic |
Epilepsy with myoclonic atonic seizures, Epilepsy with myoclonic atonic seizures |
| RS2124905507 |
SLC6A1
|
Health Risk |
Likely pathogenic |
Epilepsy with myoclonic atonic seizures, Epilepsy with myoclonic atonic seizures |
| RS2124905654 |
SLC6A1
|
Health Risk |
Likely pathogenic |
Epilepsy with myoclonic atonic seizures, Epilepsy with myoclonic atonic seizures |
| RS2124905696 |
SLC6A1
|
Health Risk |
Likely pathogenic |
Epilepsy with myoclonic atonic seizures, Epilepsy with myoclonic atonic seizures |
| RS2124906663 |
SLC6A1
|
Health Risk |
Conflicting classifications of pathogenicity |
Epilepsy with myoclonic atonic seizures, Epilepsy with myoclonic atonic seizures |
| RS2124906690 |
SLC6A1
|
Health Risk |
Likely pathogenic |
Epilepsy with myoclonic atonic seizures, Epilepsy with myoclonic atonic seizures |
| RS2124907082 |
SLC6A1
|
Health Risk |
Pathogenic |
Epilepsy with myoclonic atonic seizures, Epilepsy with myoclonic atonic seizures |
| RS2124907093 |
SLC6A1
|
Health Risk |
Likely pathogenic |
Epilepsy with myoclonic atonic seizures, Epilepsy with myoclonic atonic seizures |
| RS2124908675 |
SLC6A1
|
Health Risk |
Pathogenic |
Epilepsy with myoclonic atonic seizures, Epilepsy with myoclonic atonic seizures |
| RS2124908722 |
SLC6A1
|
Health Risk |
Conflicting classifications of pathogenicity |
Epilepsy with myoclonic atonic seizures, Epilepsy with myoclonic atonic seizures |
| RS2124908740 |
SLC6A1
|
Health Risk |
Likely pathogenic |
— |
| RS2124908824 |
SLC6A1
|
Health Risk |
Pathogenic |
Epilepsy with myoclonic atonic seizures, Epilepsy with myoclonic atonic seizures |
| RS2124912717 |
SLC6A1
|
Health Risk |
Pathogenic |
Epilepsy with myoclonic atonic seizures, Epilepsy with myoclonic atonic seizures |
| RS2124915767 |
GLS
|
Health Risk |
Pathogenic |
Developmental and epileptic encephalopathy, 71 |
| RS2124917812 |
SLC6A1
|
Health Risk |
Pathogenic |
Epilepsy with myoclonic atonic seizures, Epilepsy with myoclonic atonic seizures |
| RS2124917929 |
SLC6A1
|
Health Risk |
Likely pathogenic |
— |
| RS2124924369 |
SLC6A1
|
Health Risk |
Likely pathogenic |
Epilepsy with myoclonic atonic seizures, Epilepsy with myoclonic atonic seizures |
| RS2124924504 |
SLC6A1
|
Health Risk |
Likely pathogenic |
Epilepsy with myoclonic atonic seizures, Epilepsy with myoclonic atonic seizures |
| RS2124924511 |
SLC6A1
|
Health Risk |
Likely pathogenic |
Epilepsy with myoclonic atonic seizures, Epilepsy with myoclonic atonic seizures |
| RS2124924932 |
SLC6A1
|
Health Risk |
Pathogenic |
Epilepsy with myoclonic atonic seizures, Epilepsy with myoclonic atonic seizures |
| RS2124924957 |
SLC6A1
|
Health Risk |
Pathogenic/Likely pathogenic |
Epilepsy with myoclonic atonic seizures, Epilepsy with myoclonic atonic seizures |
| RS2124924976 |
SLC6A1
|
Health Risk |
Likely pathogenic |
Epilepsy with myoclonic atonic seizures, Epilepsy with myoclonic atonic seizures |
| RS2124925120 |
COL4A4
|
Health Risk |
Pathogenic |
Autosomal recessive Alport syndrome, Autosomal recessive Alport syndrome |
| RS2124926212 |
SLC6A1
|
Health Risk |
Likely pathogenic |
Epilepsy with myoclonic atonic seizures, Epilepsy with myoclonic atonic seizures |
| RS2124926277 |
SLC6A1
|
Health Risk |
Pathogenic |
Epilepsy with myoclonic atonic seizures, Epilepsy with myoclonic atonic seizures |
| RS2124926302 |
SLC6A1
|
Health Risk |
Likely pathogenic |
Epilepsy with myoclonic atonic seizures, Epilepsy with myoclonic atonic seizures |
| RS2124927471 |
ITPR1
|
Health Risk |
Conflicting classifications of pathogenicity |
Spinocerebellar ataxia type 29, Inborn genetic diseases |
| RS2124930786 |
UNC80
|
Health Risk |
Likely pathogenic |
Hypotonia, infantile |
| RS2124930894 |
SLC6A1
|
Health Risk |
Likely pathogenic |
Epilepsy with myoclonic atonic seizures, Epilepsy with myoclonic atonic seizures |
| RS2124930966 |
SLC6A1
|
Health Risk |
Likely pathogenic |
Epilepsy with myoclonic atonic seizures, Epilepsy with myoclonic atonic seizures |
| RS2124931871 |
SLC6A1
|
Health Risk |
Pathogenic |
Epilepsy with myoclonic atonic seizures, Epilepsy with myoclonic atonic seizures |
| RS2124932154 |
SLC6A1
|
Health Risk |
Likely pathogenic |
Epilepsy with myoclonic atonic seizures, Epilepsy with myoclonic atonic seizures |
| RS2124932157 |
SLC6A1
|
Health Risk |
Pathogenic |
Epilepsy with myoclonic atonic seizures, Epilepsy with myoclonic atonic seizures |
| RS2124932194 |
SLC6A1
|
Health Risk |
Pathogenic |
Epilepsy with myoclonic atonic seizures, Epilepsy with myoclonic atonic seizures |
| RS2124936720 |
SLC6A1
|
Health Risk |
Pathogenic |
— |
| RS2124942597 |
SLC6A1
|
Health Risk |
Pathogenic |
Epilepsy with myoclonic atonic seizures, Epilepsy with myoclonic atonic seizures |
| RS2124953130 |
UNC80
|
Health Risk |
Pathogenic |
— |
| RS2124961184 |
FANCD2
|
Health Risk |
Likely pathogenic |
Fanconi anemia, Fanconi anemia complementation group D2 |
| RS2124964267 |
UNC80
|
Health Risk |
Likely pathogenic |
— |
| RS2124966088 |
GJC2
|
Health Risk |
Pathogenic |
Hypomyelinating leukodystrophy 2, Hypomyelinating leukodystrophy 2 |
| RS2124966117 |
GJC2
|
Health Risk |
Likely pathogenic |
Hypomyelinating leukodystrophy 2, Hypomyelinating leukodystrophy 2 |
| RS2124966280 |
GJC2
|
Health Risk |
Likely pathogenic |
Hypomyelinating leukodystrophy 2, Hypomyelinating leukodystrophy 2 |
| RS2124966375 |
GJC2
|
Health Risk |
Pathogenic |
Hypomyelinating leukodystrophy 2, Hypomyelinating leukodystrophy 2 |
| RS2124966655 |
GJC2
|
Health Risk |
Likely pathogenic |
Hypomyelinating leukodystrophy 2, Hypomyelinating leukodystrophy 2 |
| RS2124966664 |
GJC2
|
Health Risk |
Likely pathogenic |
Hypomyelinating leukodystrophy 2, Abnormality of the nervous system |
| RS2124966792 |
GJC2
|
Health Risk |
Pathogenic |
Spastic paraplegia, Spastic paraplegia |
| RS2124966840 |
GJC2
|
Health Risk |
Likely pathogenic |
— |
| RS2124967068 |
GJC2
|
Health Risk |
Pathogenic |
Spastic paraplegia, Hereditary spastic paraplegia 44 |
| RS2124970985 |
FANCD2
|
Health Risk |
Likely pathogenic |
Fanconi anemia, Fanconi anemia |
| RS2124974541 |
FANCD2
|
Health Risk |
Likely pathogenic |
Fanconi anemia, Fanconi anemia complementation group D2 |
| RS2124974621 |
FANCD2
|
Health Risk |
Pathogenic |
Fanconi anemia, Fanconi anemia |
| RS2124975164 |
FANCD2
|
Health Risk |
Likely pathogenic |
Fanconi anemia complementation group D2, Fanconi anemia complementation group D2 |
| RS2124976652 |
IBA57
|
Health Risk |
Pathogenic |
Multiple mitochondrial dysfunctions syndrome 3, Hereditary spastic paraplegia 74 |
| RS2124981606 |
UNC80
|
Health Risk |
Pathogenic |
Hypotonia, infantile |
| RS2124988278 |
CAV3
|
Health Risk |
Likely pathogenic |
Abnormality of the musculature, Abnormality of the musculature |
| RS2124988406 |
CAV3
|
Health Risk |
Pathogenic/Likely pathogenic |
Long QT syndrome, Long QT syndrome |
| RS2124988641 |
CAV3
|
Health Risk |
Conflicting classifications of pathogenicity |
Long QT syndrome, Hypertrophic cardiomyopathy 1 |
| RS2124989402 |
FANCD2
|
Health Risk |
Pathogenic |
Fanconi anemia, Fanconi anemia |
| RS2124992262 |
FANCD2
|
Health Risk |
Pathogenic |
— |
| RS2124994410 |
UNC80
|
Health Risk |
Likely pathogenic |
— |
| RS2124996603 |
STAT1
|
Health Risk |
Likely pathogenic |
Immunodeficiency 31B, Autoimmune enteropathy and endocrinopathy - susceptibility to chronic infections syndrome |
| RS2124996723 |
STAT1
|
Health Risk |
Pathogenic |
Immunodeficiency 31B, Autoimmune enteropathy and endocrinopathy - susceptibility to chronic infections syndrome |
| RS2124998835 |
COL4A4
|
Health Risk |
Pathogenic |
Autosomal recessive Alport syndrome, Autosomal recessive Alport syndrome |
| RS2124999155 |
ADAM17
|
Health Risk |
Pathogenic |
Inflammatory skin and bowel disease, neonatal |
| RS2125000228 |
FANCD2
|
Health Risk |
Likely pathogenic |
Fanconi anemia, Fanconi anemia complementation group D2 |
| RS2125000306 |
STAT1
|
Health Risk |
Pathogenic |
Immunodeficiency 31B, Autoimmune enteropathy and endocrinopathy - susceptibility to chronic infections syndrome |
| RS2125000318 |
FANCD2
|
Health Risk |
Pathogenic |
Fanconi anemia, Fanconi anemia |
| RS2125000516 |
FANCD2
|
Health Risk |
Likely pathogenic |
Fanconi anemia complementation group D2, Fanconi anemia complementation group D2 |
| RS2125000569 |
FANCD2
|
Health Risk |
Likely pathogenic |
Fanconi anemia, Fanconi anemia |
| RS2125000621 |
COL4A4
|
Health Risk |
Likely pathogenic |
Focal segmental glomerulosclerosis, Focal segmental glomerulosclerosis |
| RS2125001180 |
TPO
|
Health Risk |
Likely pathogenic |
Deficiency of iodide peroxidase, Deficiency of iodide peroxidase |
| RS2125001412 |
COL4A4
|
Health Risk |
Likely pathogenic |
— |
| RS2125008314 |
XPC
|
Health Risk |
Pathogenic |
— |
| RS2125008340 |
XPC
|
Health Risk |
Pathogenic |
Xeroderma pigmentosum, group C |
| RS2125008883 |
NSDHL
|
Health Risk |
Likely pathogenic |
Malignant tumor of urinary bladder, Malignant tumor of urinary bladder |
| RS2125013239 |
UNC80
|
Health Risk |
Likely pathogenic |
— |
| RS2125015914 |
NSDHL
|
Health Risk |
Likely pathogenic |
— |
| RS2125016932 |
UNC80
|
Health Risk |
Likely pathogenic |
Hypotonia, infantile |
| RS2125019136 |
UNC80
|
Health Risk |
Pathogenic |
— |
| RS2125021778 |
XPC
|
Health Risk |
Pathogenic |
— |
| RS2125022131 |
XPC
|
Health Risk |
Likely pathogenic |
— |
| RS2125024504 |
XPC
|
Health Risk |
Likely pathogenic |
Melanoma, Melanoma |
| RS2125024977 |
XPC
|
Health Risk |
Pathogenic |
— |
| RS2125025310 |
XPC
|
Health Risk |
Pathogenic |
— |
| RS2125025539 |
XPC
|
Health Risk |
Pathogenic |
— |
| RS2125025886 |
XPC
|
Health Risk |
Pathogenic |
— |
| RS2125025992 |
XPC
|
Health Risk |
Pathogenic/Likely pathogenic |
Xeroderma pigmentosum, group C |
| RS2125026245 |
XPC
|
Health Risk |
Pathogenic |
— |
| RS2125026589 |
FANCD2
|
Health Risk |
Conflicting classifications of pathogenicity |
Fanconi anemia, Fanconi anemia complementation group D2 |